Valuation: Standard BioTools Inc.

Market Cap 239M 215M 198M 179M 335M 22.74B 341M 2.35B 948M 11.93B 899M 879M 37.75B P/E 2026 *
-6.1x
P/E 2027 * -3.81x
Enterprise Value 239M 215M 198M 179M 335M 22.74B 341M 2.35B 948M 11.93B 899M 879M 37.75B EV / Sales 2026 *
2.9x
EV / Sales 2027 * 2.92x
Free-Float
93.76%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Standard BioTools Inc.

1 day-1.61%
1 week+0.73%
1 month-17.63%
3 months-29.72%
6 months-34.32%
Current year-52.34%
1 week 0.59
Extreme 0.5881
0.63
1 month 0.59
Extreme 0.5881
0.8
Current year 0.59
Extreme 0.5881
1.67
1 year 0.59
Extreme 0.5881
1.72
3 years 0.59
Extreme 0.5881
3.04
5 years 0.59
Extreme 0.5881
5.22
10 years 0.59
Extreme 0.5881
14.9
Manager TitleAgeSince
Director of Finance/CFO 55 01/09/2024
Chief Executive Officer 63 01/10/2021
Chief Operating Officer - -
Director TitleAgeSince
Director/Board Member 72 01/04/2022
Director/Board Member 53 04/04/2022
Director/Board Member 63 01/10/2021
Date Insider Type Main position Quantity % Market Cap. Importance
20/08/26 Tax

Founder

-28,195 0.0072%
20/08/26 Tax

Executive/Senior Manager

-25,729 0.0066%
20/08/26 Tax

Chief Executive Officer

-97,627 0.0249%
Change 5-day change 1-year change 3-year change Capi.($)
-1.61%+0.73%-49.17%-69.35% 239M
-1.72%+3.44%+22.84%+56.71% 258B
-2.00%+0.75%+7.82%+20.94% 163B
-3.73%-4.48%-19.14%+64.75% 150B
-1.66%-8.12%-58.32%-17.99% 60.84B
-.--%+2.46%-11.69%-7.41% 53.31B
-2.57%+3.30%+11.59%+44.40% 53.03B
+0.84%-3.12%+7.47%+62.40% 50.67B
-3.47%+1.04%+19.48%+69.17% 49.3B
-3.61%+1.99%+32.36%+93.99% 45.46B
Average -1.95%-0.20%-3.68%+31.76% 88.42B
Weighted average by Cap. -2.10%+0.15%+4.02%+44.62%

Financials

2026 *2027 *
Net sales 82.5M 73.91M 68.05M 61.61M 115M 7.83B 117M 810M 327M 4.11B 310M 303M 13.01B 82.1M 73.56M 67.72M 61.31M 115M 7.79B 117M 806M 325M 4.09B 308M 302M 12.94B
Net income -38.8M -34.76M -32M -28.98M -54.2M -3.68B -55.2M -381M -154M -1.93B -146M -142M -6.12B -62.9M -56.35M -51.88M -46.98M -87.87M -5.97B -89.48M -618M -249M -3.13B -236M -231M -9.92B
Net Debt - -
Projected Income Statement - Annual - Standard BioTools Inc.
Logo Standard BioTools Inc.
Standard BioTools Inc. has a portfolio of technologies that help biomedical researchers develop medicines faster. The Company develops, manufactures and sells a diversified range of instrumentation, consumables, and services. The Company's Genomics business includes instruments, consumables, software, and services based upon technologies used in the identification of genes (DNA, RNA) and their functions. Its Biomark X9 system for high-throughput genomics delivers scalability for qPCR applications. Designed for researchers who require robust multiplexing capabilities, the Biomark X9 system enables the simultaneous analysis of thousands of reactions in a single run. By leveraging advanced microfluidics technology, it reduces reagent consumption while increasing throughput, making it a solution for large-scale genomic studies, clinical research, and biomarker discovery. The Biomark X9 system integrates with data analysis tools, accelerating workflows and providing comprehensive insights.
Employees
387
Date Price Change Volume
30/10/26 $0.6100 -1.61% 1,002,542
29/10/26 $0.6200 +0.49% 445,802
28/10/26 $0.6170 +0.15% 741,713
27/10/26 $0.6161 +2.68% 1,036,952
26/10/26 $0.6000 -0.92% 644,199
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BB
MarketScreener Ratings - Standard BioTools Inc.
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
0.6100USD
Average target price
1.350USD
Spread / Average Target
+121.31%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Standard BioTools Inc.